ALFERON N Rx
Generic Name and Formulations:
Interferon alfa-n3 (human leukocyte derived) 5million IU/mL; inj; contains albumin (human).
Hemispherx Biopharma, Inc.
Indications for ALFERON N:
Refractory genital warts.
≥18yrs: 0.05mL (250,000 IU) injected into the base of each wart twice weekly; max 8 wks. Max dose per session: 0.5mL (2.5million IU). Wait 3 months before retreatment unless warts enlarge or new warts develop.
<18 yrs: not recommended.
Mouse immunoglobulin, egg protein, or neomycin allergy.
Cardiovascular or severe pulmonary disease. Coagulation or seizure disorders. Severe myelosuppression. Use effective contraception during treatment. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis